Clopidogrel in acute coronary syndromes: where are we now?

Thromb Haemost. 2011 May;105(5):766-73. doi: 10.1160/TH10-10-0633. Epub 2011 Apr 7.

Authors

K R Bainey¹, T F Lai, S R Mehta

Affiliation

¹ Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.

PMID: 21475779
DOI: 10.1160/TH10-10-0633

No abstract available

Publication types

Review

MeSH terms

ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
Acute Coronary Syndrome / drug therapy*
Acute Coronary Syndrome / genetics
Acute Coronary Syndrome / mortality*
Biological Availability
Clinical Protocols
Clinical Trials as Topic
Clopidogrel
Cytochrome P-450 Enzyme System / genetics
Drug Interactions
Humans
Platelet Activation / drug effects
Polymorphism, Genetic
Purinergic P2Y Receptor Antagonists* / pharmacokinetics
Purinergic P2Y Receptor Antagonists* / pharmacology
Purinergic P2Y Receptor Antagonists* / therapeutic use
Survival Analysis
Ticlopidine / analogs & derivatives*
Ticlopidine / pharmacokinetics
Ticlopidine / pharmacology
Ticlopidine / therapeutic use
Treatment Outcome

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
ATP Binding Cassette Transporter, Subfamily B, Member 1
Purinergic P2Y Receptor Antagonists
cytochrome P-450 CYP2C subfamily
Cytochrome P-450 Enzyme System
Clopidogrel
Ticlopidine